Development and Validation of a Metabolic-related Prognostic Model for Hepatocellular Carcinoma

Junyu Huo, Liqun Wu and Yunjin Zang
Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

Received: 14 November 2020 | Revised: 3 January 2021 | Accepted: 26 January 2021 | Published: 22 February 2021

Abstract

Background and Aims: Growing evidence suggests that metabolic-related genes have a significant impact on the occurrence and development of hepatocellular carcinoma (HCC). However, the prognostic value of metabolic-related genes for HCC has not been fully revealed. Methods: mRNA sequencing and clinical data were obtained from The Cancer Genome Atlas and the GTEx Genotype-Tissue Expression comprehensive database. Differentially expressed metabolic-related genes in tumor tissues (n=374) and normal tissues (n=160) were identified by the Wilcoxon test. Time-dependent receiver operating characteristic curve analysis, univariate multivariate Cox regression analysis and Kaplan-Meier survival analysis were used to evaluate the predictive effectiveness and independence of the prognostic model. Two independent cohorts (International Cancer Genome Consortiums and GSE14520) were applied to verify the prognostic model. Results: Our study included a total of 793 patients with HCC. We constructed a risk score consisting of five metabolic-genes (BDH1, RRM2, CYP2C9, PLA2G7, and TXNRD1). For the overall survival rate, the low-risk group had a considerably higher rate than the high-risk group. Univariate and multivariate Cox regression analyses indicated that the risk score was an independent predictor for the prognosis of HCC. Conclusions: We constructed and validated a novel prognostic model, which may provide support for the precise treatment of HCC.

Citation of this article: Huo J, Wu L, Zang Y. Development and validation of a metabolic-related prognostic model for hepatocellular carcinoma. J Clin Transl Hepatol 2021; 9(2):169–179. doi: 10.14218/JCTH.2020.00114.

Keywords: Hepatocellular carcinoma; Metabolic; Prognostic; Signature.

Introduction

Hepatocellular carcinoma (HCC) is the second major cause of cancer-related death in the world. The prognosis of HCC is still not ideal, although related research has made great progress in recent years. This is mainly related to the high heterogeneity of HCC and the high diagnostic rate of advanced HCC, even with identical pathological types and clinical stages, patients’ individual responses to the same treatment can be diversified. It is worth noting that patients with HCC usually have a background of liver cirrhosis. Nevertheless, in clinical practice, which monitoring strategy is most effective for early tumor detection is uncertain. There is a pressing need to identify reliable biomarkers for the diagnosis and prognosis of HCC, to improve the survival of HCC.

In recent years, growing evidence has shown that the metabolic pattern of the cell cancerization process has changed significantly, which involves many aspects, such as glycolysis, the citric acid cycle, and oxidative phosphorylation of amino acids metabolism, fatty acid metabolism and nucleic acid metabolism, etc. This phenomenon is known as the reprogramming of energy metabolism of tumor cells, which is crucial for tumor growth. Some scholars have found that metabolic abnormalities are an important factor in the pathogenesis of HCC. Lee et al. noted that the gene expression levels involved in glycolysis and oxidative metabolism in HCC livers were much higher than those in normal livers, which was indeed relevant to an increased risk of liver cancer and may represent a potential target for the prevention of HCC. Gao et al. conducted a multidimensional proteomics study of 159 hepatitis B virus-positive liver and para cancer samples from patients in China, and found that most of the liver-specific metabolic pathway proteins (such as sugar catabolism, detoxification, ammonia and urea metabolism) in liver tumors were significantly reduced; however, the key enzymes of cholesterol metabolism (SOAT1, SOAT2, etc.) and glutamine metabolism–related proteins (GLS and GLUD2) expressed in tumors were increased significantly, suggesting that hepato-specific metabolic pathways are reprogrammed in hepatitis B virus-associated HCC. Some scholars have also proposed that metabolic changes in the tumor microenvironment (TME) can inhibit antitumor immunity (such as immune cell infiltration) by producing immunosuppressive metabolites. However, there is still a lack of research on genes related to metabolism in predicting the prognosis of patients with liver cancer. Investigations into the metabolic genes of HCC are expected to open up new avenues for the treatment of HCC.
This research study established a risk score (RS) based upon the expression levels of five metabolism-related genes and analyzed the diverse clinicopathological features correlated with the new RS. The correlations of the RS with tumor immune cell infiltration were also evaluated.

Methods

Data collection and extraction of metabolic genes

The clinical data and mRNA expression profiles of patients with HCC were taken from The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/), including 374 HCC samples and 50 normal samples; the Genotype-Tissue Expression project (GTEx; www.gtexportal.org), including 110 normal samples; the International Cancer Genome Consortium (ICGC; https://icgc.org/), including 215 patients with HCC; and the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) (GSE14520), including 235 patients with HCC. A total of 2,752 metabolic-related genes that encoded all the known human transporters and metabolic enzymes were obtained from a previously published paper, for subsequent analysis. The gene expression profiles obtained from different databases were normalized with the "combat" package in R software. The collected data were used in accordance with the data access strategies of TCGA, ICGC and GEO. All research processes and analyses were conducted in compliance with relevant regulations and guidelines. HCC clinical survival data and mRNA profile data were publicly available, and approval of the local ethics committee was not required.

Identification of differentially expressed metabolic-related genes (DEMRGs)

Using the Wilcoxon method in the R package "limma" to detect differential genes related to metabolism in HCC and normal tissues, the results of log2 fold change >1 and false discovery rate <0.05 were regarded as significantly different. The "limma" and "heatmap" packages in the R software were used to form volcano and heat maps of DEMRGs.

Annotations of DEMRGs’ functions and pathways

This research applied the R package "cluster profile" for DEMRG annotation (gene ontology [GO] and Kyoto Encyclopedia of Genes and Genomes [KEGG] pathway) to evaluate the underlying biological function of DEMRGs.

Identification of prognostic-related genes and construction of the prognostic model in the TCGA cohort

We used 343 patients (survival ≥1 month) from the TCGA dataset as the training cohort, to develop the prognostic model. During the building process of the prognostic model, we combined univariate Cox regression analysis, Lasso regression analysis, and multivariate Cox regression analyses. First, univariate Cox regression analysis was applied to screen DEMRGs associated with prognosis ($p$-value <0.001 considered significant). Next, the least absolute shrinkage and selection operator algorithm was utilized to avoid overfitting of the prognosis-related genes. During the process of this analysis, we subsampled the dataset 1,000 times and chose the genes that were repeated >900 times.

A subselection of prognosis-related genes was determined by penalty parameter tuning performed via 10-fold cross-validation. Only genes with non-zero regression coefficients were retained for subsequent multivariate Cox regression analyses (Supplementary Fig. 1). The formula of the RS was as follows: $RS = \sum \beta_i \times \log(E_i)$, where $\beta_i$ is the regression coefficient of mRNA multiplied by each normalized mRNA expression level. According to the median RS, patients were divided into two groups: the low-risk (LR) group and the high-risk (HR) group. Utilizing the Kaplan-Meier approach in the R-package “survminer” produces survival curves, and the log-rank test was used to contrast discrepancies between the two groups. Using the time-dependent receiver operating characteristic (ROC) curve analysis feature in the R package, “surv ROC” aimed to evaluate the prognostic ability of the RS.

Independence validation of the prognostic model

Univariate and multivariate Cox regression analyses were applied to detect whether the RS was an independent prognostic predictor. A value of $p<0.05$ was statistically significant.

Internal validation of the prognostic model in the TCGA cohort

We divided the patients into several subgroups for internal validation according to their pathological features (including α-fetoprotein [AFP] level, vascular invasion, histological grade, AJCC-TNM stage, new tumor after initial treatment, and individual tumor status). The analysis of survival adopted the Kaplan-Meier method, and when the log-rank test detected a value of $p<0.05$, it was considered statistically significant.

External validation of the prognostic model using multiple independent cohorts

We calculated the RS of patients in the validation cohort (ICGC, GSE14520) using the same formula established by the TCGA cohort. The patients were separated into a LR group and a HR group based on the same cutoff value. Kaplan-Meier survival analysis, ROC curve analysis and univariate and multivariate Cox regression analysis were conducted as described above.

Correlation analysis between the RS and clinicopathology

We used the chi-square test to analyze the correlation between the RS and clinicopathology (including gender, age, AJCC-TNM stage, Barcelona Clinic Liver Cancer [BCLC] stage, Cancer of the Liver Italian Program [CLIP] stage, main tumor size, histologic grade, AFP, and vascular tumor cell type). A value of $p<0.05$ was statistically significant.

Correlation analysis between RS and tumor immune cell infiltration

The CIBERSORT method (using the characteristic matrix of 547 genes to express 22 types of infiltrating immune cells) was used to measure the infiltration ratio of immune cells as a number in tumor tissues, and the samples with $p<0.05$
Huo J. et al: Hepatocellular carcinoma metabolic signature

were selected for subsequent analysis.

Gene set enrichment analysis (GSEA)

To further explore the internal mechanism of the prognostic model, we conducted GSEA on the LR and HR groups of the three independent cohorts to reveal the molecular biological characteristics of the LR and HR groups.

Results

Functional enrichment analysis and survival analysis of DEMRGs

A total of 134 metabolic-related genes were differentially expressed in HCC tissues \( n=374 \) compared with normal tissues \( n=160 \) (Fig. 1A–B). GO enrichment analysis showed that the main functions of these differentially metabolized genes included small molecule catabolism, organic acid biosynthesis, sulfur compound metabolism, carboxylic acid biosynthesis, organic acid catabolism, fatty acid metabolism, carboxylic acid catabolism and other processes (Fig. 1C). The KEGG enrichment analysis identified these genes as being prevalingly related to chemical carcinogenesis, arachidonic acid metabolism, drug metabolism, glutathione metabolism, retinol metabolism, and carbon metabolism (Fig. 1D).

Construction of the five-metabolic gene prognostic model

To facilitate the clinical application of our prognostic model, five metabolic-related genes were identified by Lasso-penalized Cox analysis to establish a predictive model. RS = \((-0.02928*BDH1 \text{ normalized expression level})+(0.04763*RRM2 \text{ normalized expression level})+(−0.0018*CYP2C9 \text{ normalized expression level})+(0.0111*PLA2G7 \text{ normalized expression level})+(0.0111*TXNRD1 \text{ normalized expression level})\). The median RS (0.967) of the TCGA cohort is a critical value that divides all patients with HCC into HR and LR groups.

Fig. 1. Identification and functional enrichment analysis of DEMRGs. (A–B) The heatmap and volcano plot of DMRGs. (C) GO enrichment analysis of DMRGs. (D) KEGG enrichment analysis of DMRGs.
Huo J. et al: Hepatocellular carcinoma metabolic signature free survival (DFS) to compare the prognosis of patients with different risks. The Kaplan-Meier curve showed that compared with the HR group, the PFS, DFS, DSS, and OS of the LR group were remarkably higher ($p<0.001$) (Fig. 2A–D).

When assessing the performance of the prognostic model by measuring the area over time under the ROC curve, the higher the area under the curve, the better was the model performance. The areas under the curve for the 1-year, 3-year, and 5-year PFS were 0.689, 0.621, and 0.683, respectively (Fig. 2D); the areas under the curve for the 1-year, 3-year, and 5-year DFS were 0.678, 0.615, and 0.691, respectively (Fig. 2C); the areas under the curve for the 1-year, 3-year, and 5-year DSS were 0.815, 0.738, and 0.674, respectively (Fig. 2B); and, the areas under the curve for the 1-year, 3-year, and 5-year OS were 0.8, 0.692, and 0.673, respectively (Fig. 2A). The RS was an independent prognostic indicator linked to PFS, DFS, DSS and OS, as presented by univariate and multivariate Cox regression analyses (Fig. 3A–D).

**Internal validation of the prognostic model in the TCGA cohort**

We divided the patients into several subgroups for internal validation according to their pathological features, consistent with previous results. Compared to the LR group, the HR group patients’ OS rates were notably lower (Fig. 4A–F).

**External validation of the prognostic model in the ICGC and GSE14520 cohorts**

Two independent datasets (ICGC, $n=215$; GSE14520, $n=235$) were used to test the prognostic value of the RS. The calculation formula of RS and the threshold value for dividing the HR and LR groups were consistent with that of the TCGA cohort. The HR patients’ OS was notably lower than that of LR patients in the two independent cohorts (Fig. 5A, D). The area under the ROC curve of the 1-year, 3-year and 5-year overall survival rates of the ICGC cohort and GSE14520 cohort were 0.750, 0.734, 0.829, 0.675, 0.671, and 0.673, respectively (Fig. 5A, D). The RS could be regarded as an independent prognostic indicator by univariate and multivariate Cox regression analyses (Fig. 5C, F). Due to the lack of relevant information about the Child/model for end-stage liver disease score, we cannot directly compare the prognostic value of the Child/model for end-stage liver disease score with the RS. However, by comparing the area under the curve values of the ROC curve between the RS and the traditional TNM staging system, we found that the RS had better performance in predicting prognosis (Supplementary Fig. 2).

**Correlation of the prognostic model with clinico-pathological characteristics**

We performed chi-square tests on three independent cohorts (TCGA, ICGC, and GSE14520) and revealed that stage, grade, vascular tumor cell type, individual neoplasm status, main tumor size, and new tumor event after initial treatment concerned the RS of patients with HCC (Supplementary Tables 1–3).

**Correlation analysis between the RS and tumor immune cell infiltration**

The CIBERSORT algorithm was used to further analyze the infiltration degree of immune cell subtypes (samples were screened by $p<0.05$). The results showed that, compared...
Huo J. et al.: Hepatocellular carcinoma metabolic signature

with the LR group, the HR group had a markedly higher infiltration degree of M2 macrophages and a lower infiltration degree of M1 macrophages (Fig. 6A–C).

Discussion

Because HCC usually occurs in the context of cirrhosis, it has high morbidity, mortality, recurrence and heterogeneity,1–3 and poses a great threat to human health. With the worldwide application of next-generation gene sequencing

GSEA

As shown in Supplementary Fig. 3, the activity of metabolism-related pathways in the LR group was significantly stronger than that in the HR group, suggesting that we may be able to find new therapeutic strategies to improve the prognosis of HCC by targeting metabolic reprogramming of HCC.
Fig. 4. Internal validation in the TCGA cohort based on clinical features. (A) AFP. (B) Tumor status. (C) Histopathological grade. (D) New tumor event after initiate treatment. (E) AJCC-TNM stage. (F) Vascular tumor cell type.
Huo J. et al: Hepatocellular carcinoma metabolic signature

Technology, people have gradually realized that the prognosis of patients with HCC is not only dependent on the traditional clinical staging system but is also related to molecular genetic factors. Growing evidence has shown that metabolic reprogramming exerts a huge function in the emergence and growth of HCC. The prognostic value of some metabolic genes has been validated, but they are still numerically inadequate. Thus, there remains a pressing need to identify more biomarkers related to the prognosis of HCC.

Compared with previous studies, this study highlighted the following aspects. First, in this study, mRNA data from TCGA, ICGC, GEO, and GTEx were integrated to study the prognostic value of metabolic-related genes in HCC. Second, we used three independent cohorts (TCGA, ICGC, and GSE14520) to construct and validate the prognostic model, making the conclusion more reliable. Third, we investigated the relationship between the prognostic...
Huo J. et al: Hepatocellular carcinoma metabolic signature

Fig. 6. Relative proportion of 22 kinds of immune cell infiltration in HR and LR patients estimated by the CIBERSORT method. (A) Barplot. (B) Heatmap. (C) Radar plot visualizing significantly different infiltration immune cells between HR and LR groups (p-value significant codes: $\leq * * * < 0.001 \leq * * < 0.01 \leq * < 0.05$).
Huo J. et al.: Hepatocellular carcinoma metabolic signature

model and tumor immune cell infiltration. Patients were classified into a LR group and a HR group, based on a uniform cutoff (0.967). In both the training cohort (TCGA) and the validation cohort (ICGC and GSE14520), the OS of the HR group was significantly lower than that of the LR group. The area under the curve of the ROC curve showed that the RS had higher specificity and sensitivity for the prediction of prognosis. Clinical correlation analysis showed that patients with a high score were found to be significantly correlated with higher tumor grade, larger main tumor size (>5 cm), age (>65 years), vessel invasion, AFP >300 ng/mL, advanced BCLC stage (B–C), advanced CLIP stage (III–IV), and these results suggest the high-RS patients had a higher degree of malignancy. For patients with the same clinical features, the prognosis of the HR group patients was markedly worse than for those of the LR group, which highlights the importance of our RS establishment because it can better reflect the heterogeneity of patients compared with the traditional clinical stage.

It has been reported that abnormal metabolism of purines (such as abnormal elevation of uric acid) is related to the appearance and growth of different malignant tumors, such as colorectal cancer metastasis, non-small cell lung cancer brain metastasis, and the prognosis of pancreatic cancer metastasis, non-small cell lung cancer. 

Vine et al.

Once reported that the expression of CYP can affect the production of arachidonic acid-derived molecules and change various downstream signal transduction pathways, thus causing cell cancerization. Yan et al.

Study found that the expression level of CYP was significantly decreased during the cancer process, while the activity of CYP was highly correlated with the expression level of the protein. The current study found that the expression level of CYP in tumor tissue was remarkably lower than that in normal tissue (Supplementary Fig. 4), and patients with high CYP2C9 expression in tumor tissues had a better prognosis (Supplementary Figs. 5–8). In addition, the reduced CYP2C9 expression level had a significant relationship with higher TNM stage and higher BCLC stage, a maximum tumor diameter of >5 cm, AFP of >300 ng/mL and vessel invasion (Supplementary Figs. 5–8). The results were similar to those of CYP4A11 in the study by Eun et al.

These findings indicate that the high CYP2C9 expression level is likely to be a favorable signal for the prognosis of HCC (Supplementary Figs. 5–8). Clinically, we can consider using CYP2C9 as a therapeutic target to further improve the prognosis of HCC.

The platelet-activating factor acetylhydrolase PLA2G7 is an effective proinflammatory and anti-inflammatory molecule involved in a variety of inflammatory processes. Nair et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.

et al.
factors have a significant impact on the clinical outcome. This study was retrospective and needs to be improved upon and verified in future multicenter prospective studies.

Conclusions

This research established and verified a reliable prognostic model for HCC patients. The five metabolic genes in the model may be promising targets for the precise treatment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Funding

None to declare.

Conflict of interest

The authors have no conflicts of interest related to this publication.

Author contributions

Designed this study (JH, LW), performed the data analyses and wrote the manuscript (JH), revision of the manuscript (JH, LW, YZ), reviewed the final version of the manuscript (JH, LW, YZ).

References

[1] Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139–152. doi:10.1038/s41575-019-0229-4.
[2] Yang JD, Hainaut P, Yang W, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global assessment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Conclusions

This research established and verified a reliable prognostic model for HCC patients. The five metabolic genes in the model may be promising targets for the precise treatment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Funding

None to declare.

Conflict of interest

The authors have no conflicts of interest related to this publication.

Author contributions

Designed this study (JH, LW), performed the data analyses and wrote the manuscript (JH), revision of the manuscript (JH, LW, YZ), reviewed the final version of the manuscript (JH, LW, YZ).

References

[1] Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139–152. doi:10.1038/s41575-019-0229-4.
[2] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global assessment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Conclusions

This research established and verified a reliable prognostic model for HCC patients. The five metabolic genes in the model may be promising targets for the precise treatment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Funding

None to declare.

Conflict of interest

The authors have no conflicts of interest related to this publication.

Author contributions

Designed this study (JH, LW), performed the data analyses and wrote the manuscript (JH), revision of the manuscript (JH, LW, YZ), reviewed the final version of the manuscript (JH, LW, YZ).

References

[1] Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139–152. doi:10.1038/s41575-019-0229-4.
[2] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global assessment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Conclusions

This research established and verified a reliable prognostic model for HCC patients. The five metabolic genes in the model may be promising targets for the precise treatment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Funding

None to declare.

Conflict of interest

The authors have no conflicts of interest related to this publication.

Author contributions

Designed this study (JH, LW), performed the data analyses and wrote the manuscript (JH), revision of the manuscript (JH, LW, YZ), reviewed the final version of the manuscript (JH, LW, YZ).

References

[1] Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139–152. doi:10.1038/s41575-019-0229-4.
[2] Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global assessment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Conclusions

This research established and verified a reliable prognostic model for HCC patients. The five metabolic genes in the model may be promising targets for the precise treatment of HCC. Therefore, it is likely to have influential potential for clinical practice in the near future.

Funding

None to declare.

Conflict of interest

The authors have no conflicts of interest related to this publication.

Author contributions

Designed this study (JH, LW), performed the data analyses and wrote the manuscript (JH), revision of the manuscript (JH, LW, YZ), reviewed the final version of the manuscript (JH, LW, YZ).

References

[1] Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:139–152. doi:10.1038/s41575-019-0229-4. 
Huo J. et al.: Hepatocellular carcinoma metabolic signature

2018;175:1289–1306.e20. doi: 10.1016/j.cell.2018.09.053.

Kajimura S, Sepe, Patam T, Eredinas-Jomagome H, Cooper MP, Ruas JL, et al. Regulation of the brown and beige fat gene programs through a POM16L/CTBP transcriptional complex. Genes Dev 2008;22:1397–1409. doi: 10.1101/gad.1666108.

Harms M, Sepe R, Brown and beige fat: development, function and therapeu-tic potential. Nat Med 2013;19:1252–1263. doi: 10.1038/nm.3361.

Wang W, Ishibashi S, Trefeny S, Shao M, Cowan AJ, Sakers A, et al. A POM16-driven metabolic signal from adipocytes regulates precursor cell fate. Cell Metab 2019;30:174–189.e5. doi: 10.1016/j.cmet.2019.05.005.

Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle 2012;11:3956–3963. doi: 10.4161/cc.22136.

Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle 2012;11:3964–3971. doi: 10.4161/cc.22137.

Sarason P, Cretu D, Musrap N, Karagiannis GS, Batruch I, Drabovich AP, et al. Quantitative proteomics reveals that enzymes of the ketogenic path-way are associated with prostate cancer progression. Mol Cell Proteomics 2013;12:1589–1601. doi: 10.1074/mcp.M112.023887.

Wu M, Liu Z, Li X, Zhang A, Lin D, Li N. Analysis of potential key genes in very early hepatocellular carcinoma. World J Surg Oncol 2019;17:77. doi: 10.1186/s12957-019-1616-6.

Yue C, Ren Y, Ge H, Liang C, Xu Y, Li G, et al. Comprehensive analysis of potential prognostic genes for the construction of a competing endogenous RNA regulatory network in hepatocellular carcinoma. Onco Targets Ther 2019;12:561–576. doi: 10.2147/OTT.S189913.

Zhou Z, Li Y, Hao H, Wang Y, Zhou Z, Wang Z, et al. Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysis. Cell Transplant 2019;28:765–865. doi: 10.1177/0963689719893950.

Kosakowska-Cholody T, Cholody WM, Hairapaksha HK, Monks A, Kar S, Wang M, et al. Growth inhibition of hepatocellular cancer cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemother Pharmacol 2009;63:769–778. doi: 10.1007/s00280-008-0801-z.

Satow R, Shitashige M, Kanai Y, Takeshita F, Ojima H, Jigami T, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma: Implications for personalized treatment in patients. Mol Cancer Ther 2015;14:2674–2686. doi: 10.1158/1535-7186.MCT-15-0274.

Eun HS, Cho SY, Lee BS, Kim S, Song IS, Chun K, et al. Cytochrome P450 4A11 expression in tumor cells: A favorable prognostic factor for hepa-tocellular carcinoma patients. J Gastroenterol Hepatol 2019;34:224–233. doi: 10.1111/jgh.14406.

Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassi A, Hale AB, et al. Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family data-sets. Hum Mol Genet 2008;17:1318–1328. doi: 10.1093/hmg/ddn020.

Nair S, Lee YH, Rousseau E, Cum M, Tataranni PA, Baier LJ, et al. Increased expression of inflammation-related genes in cultured preadipocytes/stro-mal vascular cells from obese compared with non-obese Pima Indians. Diabetologia 2005;48:1784–1788. doi: 10.1007/s00125-005-1868-2.

Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009;125:11–20. doi: 10.1007/s00439-008-0587-4.

Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellintz B, et al. Genetic variants and haplotypes of lipoprotein associated phospho-lipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost 2009;7:41–48. doi: 10.1111/j.1538-7836.2008.03216.x.

Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, in-flammation, and cancer: how are they linked? Free Radic Biol Med 2010;49:1603–1614. doi: 10.1016/j.freeradbiomed.2010.09.006.

Cho SY, Kim S, Son MJ, Rou WS, Kim SH, Eun HS, et al. Clinical sig-nificance of the thioredoxin system and thioredoxin-domain-containing protein family in hepatocellular carcinoma. Dig Dis Sci 2019;64:123–136. doi: 10.1007/s10620-018-5307-x.

Casas-Grajales S, Muriel P. Antioxidants in liver health. World J Gastrointest Pharmacol Ther 2015;6:59–72. doi: 10.4292/wjgpt.v6.i3.59.

Huang J, Xie C, Chen J, Peng J, Chu L, et al. Severely impaired and dysregulated cytochrome P450 expression and activities in hepatocellular carcinoma: Implications for personalized treatment in patients. Mol Cancer Ther 2015;14:2674–2686. doi: 10.1158/1535-7186.MCT-15-0274.

Lee D, Xu IM, Chiu DK, Leibold J, Tse AP, Bao MH, et al. Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an ef-fective therapeutic approach for hepatocellular carcinoma. Hepatology 2019;69:1768–1786. doi: 10.1002/hep.30467.

Journal of Clinical and Translational Hepatology 2021 | 169–179

179